CureVac Shareholders Face Pivotal Acquisition Decision

The biotechnology firm CureVac stands at a critical juncture, with time running out for its shareholders. As BioNTech pursues a complete acquisition of the Tübingen-based company, investors are preparing for a historic vote. The deadline to participate in an extraordinary general meeting, which will determine the company's fate, concludes today.

A definitive shareholder vote is scheduled for November 25, 2025. The agenda centers squarely on whether CureVac will maintain its independence. Shareholders are tasked with deciding on BioNTech's exchange offer and the subsequent corporate reorganization—a decision poised to have a lasting impact on the company's strategic direction.

This high-stakes situation is mirrored in the stock's recent performance. Despite an impressive rally that delivered gains of nearly 90 percent over the past twelve months, the share price is now showing signs of consolidation, trading slightly below its 50-day moving average.

Financial Results and Strategic Context

Amid the takeover developments, CureVac released its interim financial figures for 2025, which presented a mixed financial picture:

Should investors sell immediately? Or is it worth buying CureVac?

• Revenues contracted significantly to just 2.1 million euros.
• The company's operating loss showed improvement, narrowing to 116.5 million euros.
• Management confirmed that current liquidity is sufficient to fund operations into 2028.

In the context of BioNTech's strategic intentions, these fundamental metrics appear to be of secondary importance. The mRNA pioneer from Mainz is believed to be primarily interested in CureVac's technology platform and intellectual property portfolio.

Patent Dispute Resolution Adds Clarity

In a separate but crucial development, the protracted patent litigation with Pfizer and BioNTech has been resolved. This settlement concerning mRNA technology rights removes a significant overhang of uncertainty and may lead to a reassessment of the value of CureVac's intellectual property.

The central question remains: Will shareholders approve the sale to BioNTech, or will they choose to fight for the continued independence of their biotech investment? The answer will be revealed in a matter of days—a decision with the power to reshape the company's future trajectory.